Paper · 19345189
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis.
Adorno M and 14 others. Cell, 2009. Cited by 687 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Papers, record 19345189. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19345189
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasm Metastasis | Major topic |
| Smad Proteins | Major topic |
| Trans-Activators | Major topic |
| Transforming Growth Factor beta | Major topic |
| Tumor Suppressor Protein p53 | Major topic |
| Tumor Suppressor Proteins | Major topic |
| Animals | |
| Breast Neoplasms | |
| Cell Line, Tumor | |
| Humans | |
| Mice | |
| Mutation | |
| Neoplasm Transplantation | |
| Specific Pathogen-Free Organisms | |
| Transcription Factors | |
| ras Proteins |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| U01 CA84244 | NCI NIH HHS | United States | U01CA084244 | PubMed and NIH |
Source NIH RePORTER
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 19,345,184 | beta-tting on p63 as a metastatic suppressor. | https://conductscience.org/library/papers/19345184 |
Source PubMed
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by508
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 687 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,840,663 | The Amyloid State of Mutant p53 in Cancer. | JMA J | 2026 | https://conductscience.org/library/papers/42840663 | PubMed |
| 42,614,905 | Prognostic and therapeutic importance of TROP-2 and MUC-1 in non-small cell lung cancer: A systematic review and meta-analysis. | Biomed Rep | 2026 | https://conductscience.org/library/papers/42614905 | PubMed |
| 42,502,958 | Targeting molecular and genetic pathways driving tumorigenesis for precision therapy in colorectal cancer. | Cancer Biol Ther | 2026 | https://conductscience.org/library/papers/42502958 | PubMed |
| 42,318,056 | The miR-16-1-3p suppresses proliferation and invasiveness via the MDM2-p53 axis in TGF-β1 signaling in osteosarcoma. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42318056 | PubMed |
| 42,259,777 | Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42259777 | PubMed |
| 41,917,811 | Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies. | Cell Mol Biol Lett | 2026 | https://conductscience.org/library/papers/41917811 | PubMed |
| 41,642,461 | Synthesis and preclinical development of a novel 68Ga/89Zr-Labelled ανβ6-integrin targeting trimer. | EJNMMI Radiopharm Chem | 2026 | https://conductscience.org/library/papers/41642461 | PubMed |
| 41,326,842 | Mutant p53 regulates reversible subtype plasticity in pancreatic cancer. | Cell Mol Life Sci | 2025 | https://conductscience.org/library/papers/41326842 | PubMed |
| 41,037,000 | Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/41037000 | PubMed |
| 40,809,847 | Integrin factor (FAM27E3), as a metastatic marker of papillary thyroid carcinoma, through the p53 signaling pathway promoting lymph node metastasis. | Front Genet | 2025 | https://conductscience.org/library/papers/40809847 | PubMed |
1 to 10 of 508
See all 508 cited byGenes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| SMAD2 | 4,087 | PubTator's text mining | https://conductscience.org/library/genes/4087 | NCBI Gene |
| SMAD3 | 4,088 | PubTator's text mining | https://conductscience.org/library/genes/4088 | NCBI Gene |
| TGFB1 | 7,040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
| TP53 | 7,157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
| TP63 | 8,626 | PubTator's text mining | https://conductscience.org/library/genes/8626 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| PDB | GSE14491 |
Source PDB
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19345189
GET https://conductscience.org/api/papers/v1/19345189/cited_by?page=2